Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial

Matteo Trimarchi; Pietro Indelicato; Alessandro Vinciguerra; Mario Bussi

doi:10.1002/ccr3.3792

Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: The first case outside of a clinical trial

Clin Case Rep. 2021 Jan 16;9(3):1428-1432. doi: 10.1002/ccr3.3792. eCollection 2021 Mar.

Authors

Matteo Trimarchi^{1

2}, Pietro Indelicato^{1

2}, Alessandro Vinciguerra^{1

2}, Mario Bussi^{1

2}

Affiliations

¹ Otorhinolaryngology Unit Division of Head and Neck Department IRCCS San Raffaele Scientific Institute Milano Italy.
² School of Medicine Vita-Salute San Raffaele University Milano Italy.

Abstract

Treatment options for severe CRSwNP are limited. Dupilumab is a safe, well-tolerated, and effective alternative in patients with poor control of symptoms, corticosteroid-dependent disease, and high rates of recurrence of nasal polyps after surgery.

Keywords: DUPIXENT; anti–IL‐13; anti–IL‐4; biologic agents; chronic rhinosinusitis; dupilumab; monoclonal antibody; nasal polyposis; type 2 inflammation.

Publication types

Case Reports